Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2011 1
2012 2
2013 4
2014 4
2015 4
2016 4
2018 2
2019 2
2021 1
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Begaj T, Jeong D, Park JG, Runner MM, Capone A Jr, Dass AB, Drenser KA, Faia LJ, Farley ND, Garretson BR, Hassan TS, Mahmoud TH, Margherio A, Raphaelian PV, Randhawa S, Ruby AJ, Sneed S, Rao P, Wolfe JD, Williams GA. Begaj T, et al. Among authors: raphaelian pv. Retina. 2024 Feb 1;44(2):222-229. doi: 10.1097/IAE.0000000000003961. Retina. 2024. PMID: 37903288
Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study.
Park JG, Adrean SD, Begaj T, Capone A Jr, Charles S, Chen SN, Chou HD, Cohen MN, Corona ST, Faia LJ, Garg SJ, Garretson BR, Gregori NZ, Haller JA, Houghton OM, Hsu J, Jo J, Kaiser RS, Lai CC, Mahgoub MM, Mansoor M, Matoba R, Morizane Y, Nehemy MB, Raphaelian PV, Regillo CD, Ruby AJ, Runner MM, Sneed SR, Sohn EH, Spirn MJ, Vander JF, Wakabayashi T, Wolfe JD, Wykoff CC, Yonekawa Y, Yoon YH, Mahmoud TH. Park JG, et al. Among authors: raphaelian pv. Ophthalmology. 2024 Jan;131(1):66-77. doi: 10.1016/j.ophtha.2023.08.025. Epub 2023 Sep 3. Ophthalmology. 2024. PMID: 37661066
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.
Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Xue K, et al. Ophthalmol Retina. 2023 Jul;7(7):564-572. doi: 10.1016/j.oret.2023.02.008. Epub 2023 Feb 19. Ophthalmol Retina. 2023. PMID: 36803692 Clinical Trial.
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Core JQ, et al. Ophthalmol Retina. 2022 Sep;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. Epub 2022 Apr 9. Ophthalmol Retina. 2022. PMID: 35405352 Free PMC article. Clinical Trial.
Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Keenan TD, et al. Ophthalmology. 2018 Dec;125(12):1913-1928. doi: 10.1016/j.ophtha.2018.05.028. Epub 2018 Jul 27. Ophthalmology. 2018. PMID: 30060980 Free PMC article. Clinical Trial.
Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group. Pauleikhoff D, et al. Acta Ophthalmol. 2019 Nov;97(7):e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9. Acta Ophthalmol. 2019. PMID: 30968592 Free PMC article.
CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS.
Koulisis N, Moysidis SN, Govindaraju VK, Dersch AM, Capone A Jr, Covert DJ, Dadgostar H, Dass AB, Drenser KA, Engstrom RE Jr, Faia LJ, Garretson BR, Guerami AH, Hanscom TA, Mahmoud TH, Margherio AR, Oh KT, Randhawa S, Raphaelian PV, Rhoades WR, Ruby AJ, Sanfilippo CJ, Sneed SR, Trese MT, Wolfe JD, Williams GA, Yedavally S, Hassan TS. Koulisis N, et al. Among authors: raphaelian pv. Retina. 2021 Jun 1;41(6):1242-1250. doi: 10.1097/IAE.0000000000002998. Retina. 2021. PMID: 33079789
28 results